Delving into the Latest Updates on Imipramine Pamoate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Imipramine embonate, Imipramine pamoate (USP)

+ [2]

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Depressive Disorder

Originator Organization

Mallinckrodt Plc

Active Organization-

Inactive Organization

SpecGx LLC

Drug Highest PhaseWithdrawn

First Approval Date

United States (11 Mar 1973),

Depressive Disorder

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC19H24N2

InChIKeyBCGWQEUPMDMJNV-UHFFFAOYSA-N

CAS Registry50-49-7

View All Structures (2)

Rosacea is a common skin condition associated with easy blushing and red face; many patients with rosacea react to sunlight with increased redness. The purpose of this study is to determine if the use of a topical medication will help reduce sunlight induced redness and irritation in patients with rosacea.

Start Date27 Feb 2024

Sponsor / Collaborator

Wright State University School of Medicine

CTRI/2022/10/046915

/ Not yet recruitingPhase 2/3

Comparative evaluation of clinical anxiolytic efficacy of Sitadi Agada and Imipramine (TCAs) in the management of Generalized Anxiety Disorders (GAD)- A reverse Pharmacology approach.

Start Date01 Nov 2022

Sponsor / Collaborator-

100 Clinical Results associated with Imipramine Pamoate

Login to view more data

100 Translational Medicine associated with Imipramine Pamoate

Login to view more data

100 Patents (Medical) associated with Imipramine Pamoate

Login to view more data

16,552

Literatures (Medical) associated with Imipramine Pamoate

01 Apr 2025·Separation and Purification Technology

Using artificial neural networks to elucidate retention interactions on stationary phases with amine moieties dedicated to supercritical fluid chromatography

Author: Nováková, Lucie ; Plachka, Katerina ; Svec, Frantisek ; Plachká, Kateřina ; Pilařová, Veronika ; Gazarkova, Tatana ; Novakova, Lucie ; Švec, František ; Gazárková, Taťána ; Pilarova, Veronika ; Garrigues, Jean-Christophe

The retention mechanisms of small mols. on a wide range of stationary phases using different mobile phase compositions are one of the most discussed topics in current state-of-the-art supercritical fluid chromatog. (SFC).Although various theories have been published on retention behavior, prediction, and stability over time, an in-depth insight into the mechanisms is still lacking.Our study focused on the description of the retention mechanisms on columns with amine moieties, i.e., 2-ethylpyridine, 2-picolylamine, 1-aminoanthracene, and diethylamine, dedicated to SFC, using three different compositions of organic modifier, i.e., methanol, methanol + 10 mmol/L NH₃, and methanol + 2% H₂O, in CO₂.An extensive set of analytes characterized by more than 200 mol. descriptors was used.The importance of the effect of each mol. descriptor on the retention behavior was determined by artificial neural networks.Thus, the descriptors increasing and/or decreasing retention on individual columns using different mobile phase compositions were defined.The data collected over one year of column use were statistically evaluated to describe the retention behavior of small mols. on the tested stationary phases using three organic modifiers and to describe the changes in retention behavior over time.As the development of the SFC method can be laborious and time-consuming, this publication offers a detailed description of the interactions taking place between the analyte and the SFC stationary phase.Understanding these fundamental processes will enable faster development of SFC methods using quality-by-design principles.

01 Apr 2025·European Neuropsychopharmacology

Lack of antidepressant-like effect of imipramine, fluoxetine and ketamine in the forced swim test in mice: How much standardization does a positive control require?

Letter

Author: Vissintainer, Gabriela ; Martynhak, Bruno Jacson ; Lino de Oliveira, Cilene ; Medeiros, Marcela Verginia de ; Rosa, Eduardo Antonio

01 Mar 2025·Journal of Hazardous Materials

β-cyclodextrin polymers as a new sorbent for solid-phase extraction of xenobiotics in Urine

Article

Author: Liao, Yicheng ; Sun, Peizhe ; Luo, Junhuai ; Fu, Xiaoli ; Meng, Yuan ; Liu, Minqi

This study systematically assessed the performance of a newly developed solid-phase extraction (SPE) material, cellulose-supported aminated β-cyclodextrin polymer (amine-β-CDP@Cellulose), in determining 44 xenobiotics, encompassing endocrine-disrupting chemicals (EDCs), pharmaceuticals, and food additives in urine samples. The primary objective of the research was to synthesize a new sorbent, optimize the extraction protocol, and elucidate the underlying adsorption and desorption mechanisms. Following optimization, it was observed that amine-β-CDP@Cellulose achieved recoveries ranging from 80 % to 120 % for 28 of the 44 targeted xenobiotics, with only three compounds showing recoveries below 50 %. The superior extraction performance of this novel material can be attributed to the synergistic effects of its structural components: charged functional groups introduced via the cross-linking agent, the hydrophobic cyclodextrin cavity that facilitates inclusion complexation, and abundant hydroxyl groups that enhance adsorption. Additionally, the study included a comparative analysis between amine-β-CDP@Cellulose and commercially available HLB resins. This comparative analysis revealed that the amine-β-CDP@Cellulose method effectively mitigated matrix interferences while maintaining comparable extraction efficiency to the HLB-based method. Collectively, these findings suggest that amine-β-CDP@Cellulose could serve as a sustainable and cost-effective material for extracting xenobiotics from complex matrices.

100 Deals associated with Imipramine Pamoate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D08071	Imipramine Pamoate	N06AA02	DB00458

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCLC2019	Not Applicable	Small Cell Lung Cancer	15	Imipramine	vacwutmbcg(rhwugwsvuz) = udvuadupnq uvjlnzbywg (yqiyvehidg )	-	08 Sep 2019
AUA2018	Not Applicable	Diabetes Mellitus	-	Imipramine+pseudoephedrine	jmxnpuxxpz(xmrhsijcvw) = jhbbaybiwc rvqugwenqu (ijlejcpfrj ) View more	-	01 Apr 2018
NCT00404755 (CTgov)	Phase 4	Depressive Disorder, Major	17	bupropion (Bupropion)	wqrfdtwluj(llzkrstzho) = jdjjeraegl cwzzouengt (fpiaaikzpr, efvckscqgf - tayzdgeafi) View more	-	15 Mar 2018
NCT00404755 (CTgov)	Phase 4	Depressive Disorder, Major	17	Escitalopram (Escitalopram)	wqrfdtwluj(llzkrstzho) = hxpxtwfdgz cwzzouengt (fpiaaikzpr, krfmywzbjh - lnsrwyfwmx) View more	-	15 Mar 2018
NCT01107353 (CTgov)	Not Applicable	Depressive Disorder	39	Imipramine Pamoate (First Imipramine Pamoate, Then Tofranil-PM)	kivavhgodi(odnfjhlymh) = xjhdeuzpip rqpmjkmaiw (mgdzmukbjd, vctdxxjhfq - xpooxypabj) View more	-	15 Jan 2014
NCT01107353 (CTgov)	Not Applicable	Depressive Disorder	39	Imipramine Pamoate (First Tofranil PM, Then Imipramine Pamoate)	kivavhgodi(odnfjhlymh) = pckuvpniua rqpmjkmaiw (mgdzmukbjd, pwxmhltruv - erlvboeurr) View more	-	15 Jan 2014